Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 19/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.66 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634809 | 0.86 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634085 | 0.85 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634436 | 0.84 | SLC6A2 (0.82) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634374 | 0.83 | SLC6A2 (0.83) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634795 | 0.83 | SLC6A2 (0.83) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| Hydrochloric Acid SCHEMBL6413316 | 0.82 | SLC6A2 (0.82) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634408 | 0.82 | SLC6A2 (0.82) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634112 | 0.82 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634137 | 0.82 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL6416013 | 0.82 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638933-B1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2008-06-11 | — | — | EP | claimed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | claimed |
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | PFIZER INC | 2005-06-23 | — | — | US | claimed |
| US-20080306123-A1 | NOVEL COMPOUNDS | PFIZER INC. (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1638933-B1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2008-06-11 | — | — | EP | disclosed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | PFIZER INC | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | AOC3, ADRB3, HTR3C | SLC6A2 117/4885SLC6A4 193/4885SLC6A3 115/4885 |
| US-20080306123-A1 | NOVEL COMPOUNDS | ADRB3, HTR3A, HTR3C | SLC6A2 51/4885SLC6A4 93/4885SLC6A3 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.